14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DXCM vs ZBH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Zimmer Biomet Holdings, Inc. (ZBH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin).
Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile ZBH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment39.4% of Rev ($2.01B)
90D Engineering Disclosures0 Published
ZBH Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $19.2B market capitalization and 16.7% operating margin.
OpEx & R&D Reinvestment52.6% of Rev ($4.51B)
90D Engineering Disclosures0 Published
Investor FAQ DXCM vs ZBH Key Questions & Quantitative Answers
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Zimmer Biomet Holdings, Inc. (ZBH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile ZBH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with ZBH at +3.1% YoY revenue growth and -13.8% YoY earnings growth on $8.57B TTM revenue (69.3% gross margin, 16.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while ZBH shifted +3.8%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 52.6% of Rev ($4.51B) (0 disclosures) for ZBH.
ZBH screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas ZBH trades at 11.3x Forward P/E, 25.6x Trailing P/E, 2.17x PEG, and 3.1x EV/Revenue (17.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus ZBH (6.0% ROE) capital efficiency.
In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, ZBH carries 133.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.40β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.